Steven Cohen Crinetics Pharmaceuticals, Inc. Put Options Transaction History
Point72 Asset Management, L.P.
- $40.1 Billion
- Q1 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
Others Institutions Holding CRNX
# of Institutions
235Shares Held
87MCall Options Held
40KPut Options Held
162K-
Vanguard Group Inc Valley Forge, PA9.31MShares$291 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.89MShares$215 Million0.05% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.24MShares$195 Million2.28% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$195 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.11MShares$160 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.68B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...